MDCO-216 News - LARVOL Sigma

|||||||||| MDCO-216 / Novartis, apoA-I (CSL112) / CSL Behring
Review, Journal: ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. (Pubmed Central) - Jun 30, 2022
Phase II-b studies of MDCO-216 and CER-001 failed to produce a significant reduction in coronary plaque volume as assessed by IVUS. However, the investigation to determine whether the direct infusion of a reconstituted apoA-I reduces post-myocardial infarction coronary events is being tested using CSL112, which is dosed at a higher level than MDCO-216 and CER-001 and has more favorable pharmacodynamics.

|||||||||| MDCO-216 / Novartis, apoA-I (CSL112) / CSL Behring
Review, Journal: Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases. (Pubmed Central) - Jan 27, 2022
Moreover, success stories, lessons, and interpretations of the utility and functionality of these HDL-mimicking nanotherapeutics will be an integral part of this article. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease.

|||||||||| MDCO-216 / Novartis
Preclinical, Journal: Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. (Pubmed Central) - Dec 16, 2020
MDCO-216 completely reversed cardiac dysfunction and abolished heart failure as evidenced by the normal lung weight and normal biomarkers of heart failure. In conclusion, apo A-I nanoparticles constitute an effective treatment for established hypertension-associated HFpEF.

|||||||||| Biomarker, Review, Journal: Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018. (Pubmed Central) - Feb 7, 2020
Of these, six candidates (MDCO-216, TRV027, ubenimex, sodium nitrite, losmapimod, and bococizumab) were dropped for lack of clinical efficacy, the other six for strategic or unspecified reasons...Four candidate developments (OPC-108459, ONO-4232, GSK-2798745, and TAK-536TCH) were run without biomarkers, which could be used as surrogate endpoints in the 12 cardiovascular drugs discontinued from 2016 to 2018. This review will be useful for those involved in the field of drug discovery and development, and for those interested in the treatment of cardiovascular disease.

|||||||||| MDCO-216 / Novartis
Clinical, Journal: Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. (Pubmed Central) - Oct 8, 2019
P1/2
Among patients with an acute coronary syndrome, infusing MDCO-216 did not produce an incremental plaque regression in the setting of contemporary statin therapy. ClinicalTrials.gov Identifier: (NCT02678923).

|||||||||| MDCO-216 / The Medicines Company
Preclinical, Journal: Successful treatment of established heart failure in mice with recombinant HDL (Milano). (Pubmed Central) - Sep 26, 2019
MDCO-216 improves diastolic function, induces regression of interstitial fibrosis, and normalises lung weight in mice with established heart failure. Recombinant HDL may emerge as a treatment modality in heart failure.

|||||||||| MDCO-216 / The Medicines Company
Preclinical, Journal: Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice. (Pubmed Central) - Jun 28, 2019
...To investigate the effect of reconstituted HDL on HF, eight intraperitoneal administrations of MDCO-216 (100 mg/kg protein concentration) or of an identical volume of control buffer were executed with a 48-h interval starting at the age of 28 weeks...No effect of control buffer injection was observed. In conclusion, reconstituted HDL reverses HF in type 2 diabetic mice.



	Diseases Companies Products Productz Mechanisms of Action Sites